Therapy News and Research

RSS

Vertex reports 75% patients with HCV achieve viral cure with 12-week telaprevir-based combination regimen

Vertex Pharmaceuticals Incorporated today announced that 75% of people chronically infected with genotype 1 hepatitis C virus (HCV) who had not previously been treated achieved a sustained viral response (SVR or viral cure) after receiving a 12-week telaprevir-based combination regimen, followed by treatment with pegylated-interferon and ribavirin alone, in the Phase 3 ADVANCE trial.

26 May 2010

KCI to feature expanded line of NPTP products and services at EWMA congress

Kinetic Concepts, Inc. today announced the company will feature its expanded line of negative pressure technology platform products and services at the annual European Wound Management Association congress in Geneva, Switzerland. Highlighting the company's commitment to innovative therapies, the new product line will improve the portability and adoption of V.A.C. Therapy, while further specializing the clinical application of negative pressure.

26 May 2010

Osteopathic manipulative medicine reduces length of hospital stays for pneumonia patients: Research

Older patients battling pneumonia spent less time in the hospital when treated using osteopathic manipulative medicine - a drug-free form of hands-on medical care focusing on increasing muscle motion - in addition to conventional care, recently published research shows.

26 May 2010

Researchers examine association between use of antibiotics and outcomes among patients with COPD

Among patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease, those who received antibiotics in the first 2 hospital days had improved outcomes, such as a lower likelihood of mechanical ventilation and fewer readmissions, compared to patients who received antibiotics later or not at all, according to a study in the May 26 issue of JAMA.

26 May 2010

GTx reports top line results from toremifene Phase III clinical trial for prostate cancer

GTx, Inc. today announced top line results of the Phase III clinical trial evaluating toremifene 20 mg, a selective estrogen receptor modulator, for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia, or PIN, a premalignant lesion of the prostate.

26 May 2010

Pioneers Memorial Healthcare District purchases QuadraMed CPR EHR solution

QuadraMed® Corporation today announced that Pioneers Memorial Healthcare District in Brawley, Calif., has selected the QuadraMed CPR (QCPR™) electronic health record (EHR) solution and several other QuadraMed applications to help improve the quality of patient care, increase operational efficiencies and enhance revenues. Also included in the purchase are QuadraMed's identity management, enterprise scheduling, revenue management and nurse-staffing management solutions.

25 May 2010

Genzyme's Lumizyme for Pompe disease receives FDA marketing approval

Genzyme Corporation announced today that the FDA has granted U.S. marketing approval for Lumizyme™ (alglucosidase alfa), produced at the 4000 liter (L) bioreactor scale at its manufacturing facility in Geel, Belgium. Lumizyme is the first treatment approved in the United States specifically to treat patients with late-onset Pompe disease.

25 May 2010

Rockwell Medical's SFP Phase IIb data accepted for presentation at XLVII ERA-EDTA Congress

Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, announced today that Phase IIb data for its lead drug candidate Soluble Ferric Pyrophosphate (SFP) have been accepted for presentation at the XLVII European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress, organized in collaboration with the Deutsche Gesellschaft fur Nephrologie (DGfN) in Munich, Germany, June 25-28, 2010.

25 May 2010

Medtronic fiscal year 2010 revenue up 8% to $15.817 billion

Medtronic, Inc. today announced financial results for its fourth quarter and fiscal year ended April 30, 2010.

25 May 2010

Five Prime Therapeutics, Fast Forward partner to develop Multiple Sclerosis therapeutic candidate

Five Prime Therapeutics, Inc., a leader in the discovery and development of innovative biologics, and Fast Forward, LLC, a subsidiary of the National Multiple Sclerosis Society, today announced an alliance to fund the development of a FivePrime pre-clinical stage therapeutic candidate for treatment of Multiple Sclerosis (MS). Fast Forward will commit up to $1 million to fund the advancement of the therapeutic candidate.

25 May 2010

Valocor Therapeutics acquires, licenses dermatology therapeutic programs from QLT

Valocor Therapeutics, Inc., a newly formed company focused on the development of innovative therapies for the treatment of dermatologic conditions, today announced the acquisition and license of certain dermatology therapeutic programs from QLT Inc.. This transaction was facilitated by a seed financing for Valocor led by the Working Opportunity Fund, which is managed by GrowthWorks Capital Ltd.

25 May 2010

FDA grants priority review for Alkermes' VIVITROL sNDA for opioid dependence

Alkermes, Inc. today announced that the supplemental New Drug Application (sNDA) for VIVITROL® (naltrexone for extended-release injectable suspension) for opioid dependence has been designated a priority review by the U.S. Food and Drug Administration (FDA).

25 May 2010

Cytochroma reports positive Phase 1/2 results for CTAP101 Capsules in non-dialysis CKD patients

Cytochroma today announced positive Phase 1/2 results for CTAP101 Capsules, a product being developed to treat secondary hyperparathyroidism (SHPT) associated with vitamin D insufficiency in non-dialysis chronic kidney disease (CKD) patients. The study demonstrated that a single dose of CTAP101 Capsules was safe, effective and well tolerated.

25 May 2010

Spectrum Pharmaceuticals to present clinical data on belinostat at ASCO 2010

Spectrum Pharmaceuticals, Inc., a commercial stage biotechnology company with a primary focus in hematology and oncology, today announced that clinical data on belinostat will be presented at the 2010 Annual Meeting of the American Society of Clinical Oncology, to be held June 4-8, 2010 at the McCormick Place Convention Center in Chicago, Illinois.

25 May 2010

Anaheim Regional Medical Center uses Arctic Sun cooling device to protect a patient from brain damage

A day after delivering her fourth child at Anaheim Regional Medical Center in Anaheim, California last December, 34-year-old Brynn Ervin suffered a cardiac arrest, the result of massive blood clots lodged in the main arteries that take blood to her lungs. Desperate to save the life of the young mother, the cardiac arrest team performed 95 minutes of CPR.

25 May 2010

ImmunoGen to present clinical data on IMGN388 solid tumor compound at 2010 ASCO

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that there will be several clinical data presentations for compounds utilizing the Company's Targeted Antibody Payload (TAP) technology at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago on June 4-8, 2010.

25 May 2010

Researchers develop new device that can change current landscape of chronic wound management

Complex wounds affect more patients in the United States than heart attack and stroke combined, and five to seven million Americans with complex wounds account for over $20 billion in healthcare expenditures. About 150,000 amputations a year result from complex wounds, while about 80,000 are attributed to diabetes and peripheral arterial disease.

25 May 2010

t2c001 product obtains certificate under EMA regulations for ATMPs

t2cure GmbH, a biopharmaceutical company developing and marketing stem cell-based regenerative therapies, announced today that the quality of its lead product t2c001 has been certified by the European Medicines Agency.

25 May 2010

Mayo Clinic becomes first hospital in the U.S. to discharge a patient with artificial heart

Mayo Clinic Hospital in northeast Phoenix made history on May 3, 2010, when it became the first hospital in the U.S. to discharge a patient with an artificial heart - after he had been hospitalized for more than two years.

25 May 2010

DAPT Study expands into seven countries in the EU: HCRI

The Harvard Clinical Research Institute announced today that the DAPT Study has expanded into seven countries in the European Union. John Irving, MBChB, MRCP, M.D., consultant cardiologist at Ninewells Hospital in Dundee, United Kingdom, was the first European investigator to enroll patients into the study.

25 May 2010

Therapy News and Research

Vertex reports 75% patients with HCV achieve viral cure with 12-week telaprevir-based combination regimen

KCI to feature expanded line of NPTP products and services at EWMA congress

Osteopathic manipulative medicine reduces length of hospital stays for pneumonia patients: Research

Researchers examine association between use of antibiotics and outcomes among patients with COPD

GTx reports top line results from toremifene Phase III clinical trial for prostate cancer

Pioneers Memorial Healthcare District purchases QuadraMed CPR EHR solution

Genzyme's Lumizyme for Pompe disease receives FDA marketing approval

Rockwell Medical's SFP Phase IIb data accepted for presentation at XLVII ERA-EDTA Congress

Medtronic fiscal year 2010 revenue up 8% to $15.817 billion

Five Prime Therapeutics, Fast Forward partner to develop Multiple Sclerosis therapeutic candidate

Valocor Therapeutics acquires, licenses dermatology therapeutic programs from QLT

FDA grants priority review for Alkermes' VIVITROL sNDA for opioid dependence

Cytochroma reports positive Phase 1/2 results for CTAP101 Capsules in non-dialysis CKD patients

Spectrum Pharmaceuticals to present clinical data on belinostat at ASCO 2010

Anaheim Regional Medical Center uses Arctic Sun cooling device to protect a patient from brain damage

ImmunoGen to present clinical data on IMGN388 solid tumor compound at 2010 ASCO

Researchers develop new device that can change current landscape of chronic wound management

t2c001 product obtains certificate under EMA regulations for ATMPs

Mayo Clinic becomes first hospital in the U.S. to discharge a patient with artificial heart

DAPT Study expands into seven countries in the EU: HCRI

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News